Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.68)
# 773
Out of 12,268 analysts
417
Total ratings
43.2%
Success rate
16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintained: Buy | $19 → $21 | $13.53 | +55.21% | 37 | May 20, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.64 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $28 → $30 | $12.60 | +138.10% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $86 → $80 | $50.36 | +58.86% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Maintained: Buy | $8 → $10 | $4.72 | +111.86% | 6 | Nov 20, 2025 | |
| TSHA Taysha Gene Therapies | Maintained: Buy | $6 → $8 | $5.49 | +45.72% | 43 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintained: Buy | $20 → $22 | $11.27 | +95.21% | 26 | Nov 4, 2025 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $9 | $4.22 | +113.27% | 4 | Oct 31, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $29.10 | +54.64% | 4 | Oct 13, 2025 | |
| JSPR Jasper Therapeutics | Maintained: Buy | $12 → $6 | $0.903 | +564.45% | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.75 | +642.86% | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $6.62 | +126.59% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.53 | - | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $50.15 | -0.30% | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $2.97 | +102.02% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.60 | +53.85% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.33 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $3.50 | n/a | 23 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $12.50 | n/a | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.76 | n/a | 3 | May 7, 2020 |
Relay Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $19 → $21
Current: $13.53
Upside: +55.21%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.64
Upside: -
Intellia Therapeutics
Apr 28, 2026
Maintained: Buy
Price Target: $28 → $30
Current: $12.60
Upside: +138.10%
CRISPR Therapeutics AG
Jan 30, 2026
Maintained: Buy
Price Target: $86 → $80
Current: $50.36
Upside: +58.86%
Nuvation Bio
Nov 20, 2025
Maintained: Buy
Price Target: $8 → $10
Current: $4.72
Upside: +111.86%
Taysha Gene Therapies
Nov 5, 2025
Maintained: Buy
Price Target: $6 → $8
Current: $5.49
Upside: +45.72%
Benitec Biopharma
Nov 4, 2025
Maintained: Buy
Price Target: $20 → $22
Current: $11.27
Upside: +95.21%
Foghorn Therapeutics
Oct 31, 2025
Maintained: Buy
Price Target: $9
Current: $4.22
Upside: +113.27%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $29.10
Upside: +54.64%
Jasper Therapeutics
Sep 22, 2025
Maintained: Buy
Price Target: $12 → $6
Current: $0.903
Upside: +564.45%
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.75
Upside: +642.86%
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $6.62
Upside: +126.59%
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.53
Upside: -
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $50.15
Upside: -0.30%
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $2.97
Upside: +102.02%
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $2.60
Upside: +53.85%
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $14.33
Upside: n/a
Mar 14, 2025
Maintained: Buy
Price Target: $6
Current: $3.50
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jan 26, 2023
Maintained: Buy
Price Target: $18
Current: $12.50
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.76
Upside: n/a